{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:08:08Z","timestamp":1790770088154,"version":"4.1.0"},"reference-count":31,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T00:00:00Z","timestamp":1596153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["AZV 17-28980A"],"award-info":[{"award-number":["AZV 17-28980A"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["RVO-VFN64165"],"award-info":[{"award-number":["RVO-VFN64165"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["DRO (FNOl, 00098892)"],"award-info":[{"award-number":["DRO (FNOl, 00098892)"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001824","name":"Grantov\u00e1 Agentura \u010cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["GA20-25308S"],"award-info":[{"award-number":["GA20-25308S"]}],"id":[{"id":"10.13039\/501100001824","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007397","name":"Univerzita Karlova v Praze","doi-asserted-by":"publisher","award":["UNCE\/MED\/016"],"award-info":[{"award-number":["UNCE\/MED\/016"]}],"id":[{"id":"10.13039\/100007397","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001823","name":"Ministerstvo \u0160kolstv\u00ed, Ml\u00e1de\u017ee a T\u011blov\u00fdchovy","doi-asserted-by":"publisher","award":["PROGRES Q26\/LF1"],"award-info":[{"award-number":["PROGRES Q26\/LF1"]}],"id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001823","name":"Ministerstvo \u0160kolstv\u00ed, Ml\u00e1de\u017ee a T\u011blov\u00fdchovy","doi-asserted-by":"publisher","award":["PROGRES Q28\/LF1"],"award-info":[{"award-number":["PROGRES Q28\/LF1"]}],"id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Palacky University","award":["IGA-LF-2019-001"],"award-info":[{"award-number":["IGA-LF-2019-001"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Mantle cell lymphoma (MCL) is a subtype of B-cell lymphoma with a large number of recurrent cytogenetic\/molecular aberrations. Approximately 5\u201310% of patients do not respond to frontline immunochemotherapy. Despite many useful prognostic indexes, a reliable marker of chemoresistance is not available. We evaluated the prognostic impact of seven recurrent gene aberrations including tumor suppressor protein P53 (TP53) and cyclin dependent kinase inhibitor 2A (CDKN2A) in the cohort of 126 newly diagnosed consecutive MCL patients with bone marrow involvement \u22655% using fluorescent in-situ hybridization (FISH) and next-generation sequencing (NGS). In contrast to TP53, no pathologic mutations of CDKN2A were detected by NGS. CDKN2A deletions were found exclusively in the context of other gene aberrations suggesting it represents a later event (after translocation t(11;14) and aberrations of TP53, or ataxia telangiectasia mutated (ATM)). Concurrent deletion of CDKN2A and aberration of TP53 (deletion and\/or mutation) represented the most significant predictor of short EFS (median 3 months) and OS (median 10 months). Concurrent aberration of TP53 and CDKN2A is a new, simple, and relevant index of chemoresistance in MCL. Patients with concurrent aberration of TP53 and CDKN2A should be offered innovative anti-lymphoma therapy and upfront consolidation with allogeneic stem cell transplantation.<\/jats:p>","DOI":"10.3390\/cancers12082120","type":"journal-article","created":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T04:15:31Z","timestamp":1596168931000},"page":"2120","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Concurrent TP53 and CDKN2A Gene Aberrations in Newly Diagnosed Mantle Cell Lymphoma Correlate with Chemoresistance and Call for Innovative Upfront Therapy"],"prefix":"10.3390","volume":"12","author":[{"given":"Diana","family":"Malarikova","sequence":"first","affiliation":[{"name":"First Department of Internal Medicine-Hematology, General University Hospital and First Faculty of Medicine, Charles University in Prague, 12808 Prague, Czech Republic"},{"name":"Institute of Pathological Physiology, First Faculty of Medicine, Charles University in Prague, 12853 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adela","family":"Berkova","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine-Hematology, General University Hospital and First Faculty of Medicine, Charles University in Prague, 12808 Prague, Czech Republic"},{"name":"Center of Oncocytogenomics, Institute of Clinical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University in Prague, 12853 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6758-3074","authenticated-orcid":false,"given":"Ales","family":"Obr","sequence":"additional","affiliation":[{"name":"Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, 77515 Olomouc, Czech Repulbic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Blahovcova","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine-Hematology, General University Hospital and First Faculty of Medicine, Charles University in Prague, 12808 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2966-3687","authenticated-orcid":false,"given":"Michael","family":"Svaton","sequence":"additional","affiliation":[{"name":"CLIP, Department of Pediatric Hematology\/Oncology, Second Faculty of Medicine and University Hospital in Motol, 15006 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Forsterova","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine-Hematology, General University Hospital and First Faculty of Medicine, Charles University in Prague, 12808 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8969-4197","authenticated-orcid":false,"given":"Eva","family":"Kriegova","sequence":"additional","affiliation":[{"name":"Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, 77515 Olomouc, Czech Repulbic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Prihodova","sequence":"additional","affiliation":[{"name":"Center of Oncocytogenomics, Institute of Clinical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University in Prague, 12853 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenka","family":"Pavlistova","sequence":"additional","affiliation":[{"name":"Center of Oncocytogenomics, Institute of Clinical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University in Prague, 12853 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Petrackova","sequence":"additional","affiliation":[{"name":"Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, 77515 Olomouc, Czech Repulbic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzana","family":"Zemanova","sequence":"additional","affiliation":[{"name":"Center of Oncocytogenomics, Institute of Clinical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University in Prague, 12853 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Trneny","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine-Hematology, General University Hospital and First Faculty of Medicine, Charles University in Prague, 12808 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7786-9378","authenticated-orcid":false,"given":"Pavel","family":"Klener","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine-Hematology, General University Hospital and First Faculty of Medicine, Charles University in Prague, 12808 Prague, Czech Republic"},{"name":"Institute of Pathological Physiology, First Faculty of Medicine, Charles University in Prague, 12853 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,7,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Klener, P. (2019). Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20184417"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1200\/JCO.2015.63.5904","article-title":"Mantle Cell Lymphoma","volume":"34","author":"Cheah","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/ajh.25487","article-title":"Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management","volume":"94","author":"Jain","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1182\/blood-2018-03-791392","article-title":"Update on mantle cell lymphoma","volume":"132","author":"Maddocks","year":"2018","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/hon.2596","article-title":"The modern approach to mantle cell lymphoma","volume":"37","author":"Rule","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_6","first-page":"2988","article-title":"The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells","volume":"123","author":"Zhang","year":"2014","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"18250","DOI":"10.1073\/pnas.1314608110","article-title":"Landscape of somatic mutations and clonal evolution in mantle cell lymphoma","volume":"110","author":"Bea","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41417-018-0022-5","article-title":"Genomic landscape and prognostic analysis of mantle cell lymphoma","volume":"25","author":"Yang","year":"2018","journal-title":"Cancer Gene Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"58638","DOI":"10.18632\/oncotarget.10716","article-title":"Gene mutations and actionable genetic lesions in mantle cell lymphoma","volume":"7","author":"Ahmed","year":"2016","journal-title":"Oncotarget"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1182\/blood-2011-11-391474","article-title":"Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma","volume":"119","author":"Kridel","year":"2012","journal-title":"Blood"},{"key":"ref_11","unstructured":"Wang, L., Tang, G., Medeiros, L.J., Xu, J., Huang, W., Yin, C.C., Wang, M., Jain, P., Lin, P., and Li, S. (2020). MYC rearrangement but not extra MYC copies is an independent prognostic factor in patients with mantle cell lymphoma. Haematologica, 105."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.3324\/haematol.2018.214056","article-title":"KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: A FIL study","volume":"105","author":"Ferrero","year":"2020","journal-title":"Haematologica"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1182\/bloodadvances.2019001350","article-title":"Genetic mutations and features of mantle cell lymphoma: A systematic review and meta-analysis","volume":"4","author":"Hill","year":"2020","journal-title":"Blood Adv."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1200\/JCO.2015.63.8387","article-title":"Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results from Randomized Trials of the European Mantle Cell Lymphoma Network","volume":"34","author":"Hoster","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_16","first-page":"1903","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","author":"Eskelund","year":"2017","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1182\/blood-2018-03-838136","article-title":"A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome","volume":"132","author":"Clot","year":"2018","journal-title":"Blood"},{"key":"ref_18","first-page":"604","article-title":"High-Dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma","volume":"126","author":"Klapper","year":"2015","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.clml.2018.07.282","article-title":"TP53 Mutation and Complex Karyotype Portends a Dismal Prognosis in Patients with Mantle Cell Lymphoma","volume":"18","author":"Obr","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3389\/fonc.2019.00851","article-title":"Standardization of Sequencing Coverage Depth in NGS: Recommendation for Detection of Clonal and Subclonal Mutations in Cancer Diagnostics","volume":"9","author":"Petrackova","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/sim.7803","article-title":"Standard errors and confidence intervals for variable importance in random forest regression, classification, and survival","volume":"38","author":"Ishwaran","year":"2019","journal-title":"Stat. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"ref_23","first-page":"3322","article-title":"Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: Results from a detailed genetic characterization with long-term follow-up","volume":"112","author":"Zenz","year":"2008","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/gcc.22849","article-title":"Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A\/B loss, and TP53 mutations: A multi-institutional study","volume":"59","author":"Streich","year":"2020","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0002-9440(10)61686-0","article-title":"Overall survival in aggressive B-Cell lymphomas is dependent on the accumulation of alterations in p53, p16, and p27","volume":"159","author":"Saez","year":"2001","journal-title":"Am. J. Pathol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/s41467-019-08578-3","article-title":"Genomic and transcriptomic changes complement each other in the pathogenesis of sporadic Burkitt lymphoma","volume":"10","author":"Lopez","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_27","first-page":"227892","article-title":"Prognostic impact of somatic mutations in diffuse large B-Cell lymphoma and relationship to cell-of-origin: Data from the phase III GOYA study","volume":"105","author":"Bolen","year":"2019","journal-title":"Haematologica"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1182\/blood-2018-01-791376","article-title":"Biology and treatment of Richter syndrome","volume":"131","author":"Rossi","year":"2018","journal-title":"Blood"},{"key":"ref_29","first-page":"2673","article-title":"Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome","volume":"122","author":"Chigrinova","year":"2013","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/gcc.22184","article-title":"Amplification of 2p as a genomic marker for transformation in lymphoma","volume":"53","author":"Kwiecinska","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.celrep.2013.12.027","article-title":"Genetics of follicular lymphoma transformation","volume":"6","author":"Pasqualucci","year":"2014","journal-title":"Cell Rep."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/8\/2120\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:53:12Z","timestamp":1760176392000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/8\/2120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,31]]},"references-count":31,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8]]}},"alternative-id":["cancers12082120"],"URL":"https:\/\/doi.org\/10.3390\/cancers12082120","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,31]]}}}